Hydrogen peroxide enhances radiation-induced apoptosis and inhibition of melanoma cell proliferation

Anticancer Research

Volumn 33, Issue 5, 2013, Pages 1799-1807

  Fang, Yujiang ^a   Moore, Bradley J ^a   Bai, Qian ^a   Cook, Kathryn M ^a   Herrick, Elizabeth J ^a   Nicholl, Michael B ^a  

^a University of Missouri   (United States)

Author keywords

Apoptosis; Hydrogen peroxide; Melanoma; Proliferation; Radiation

Indexed keywords

CASPASE 3; CYCLIN D; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; HYDROGEN PEROXIDE; PROTEIN BCL 2; PROTEIN P15;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MELANOMA; MELANOMA CELL; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION; RADIOSENSITIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

APOPTOSIS; HYDROGEN PEROXIDE; MELANOMA; PROLIFERATION; RADIATION;

APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GAMMA RAYS; HUMANS; HYDROGEN PEROXIDE; IMMUNOENZYME TECHNIQUES; MELANOMA; OXIDANTS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 84878211923     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Atkins MB: Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 12: 2353s-2358s, 2006.
2. Siegel R, Ward E and Jemal A: Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236, 2011.
3. Nicholl MB, Elashoff D, Takeuchi H, Morton DL and Hoon DS: Molecular up-staging based on paraffin-embedded sentinel lymph nodes: Ten-year follow-up confirms prognostic utility in melanoma patients. Ann Surg 253: 116-122, 2011.
4. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA and BRIM-3 Study Group: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011.
5. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A and Urba WJ: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723, 2010.
6. Beddingfield FC 3rd: The melanoma epidemic: res ipsa loquitur. Oncologist 8: 459-465, 2003.
7. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH and Morabito A: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19: 3622-3634, 2001. (Pubitemid 32786275)
8. Bastiaannet E, Beukema JC and Hoekstra HJ: Radiation therapy following lymph node dissection in melanoma patients: Treatment, outcome and complications. Cancer Treat Rev 31: 18-26, 2005. (Pubitemid 40246987)
9. Perlis C and Herlyn M: Recent advances in melanoma biology. Oncologist 9: 182-187, 2004. (Pubitemid 38452117)
10. Atallah E and Flaherty L: Treatment of metastatic malignant melanoma. Curr Treat Options Oncol 6: 185-193, 2005. (Pubitemid 40945448)
11. 2 for platelet-derived growth factor signal transduction. Science 270: 296-299, 1995.
12. Griendling KK and Harrison DG: Dual role of reactive oxygen species in vascular growth. Circ Res 85: 562-563, 1999. (Pubitemid 29431958)
13. Dalton TP, Shertzer HG and Puga A: Regulation of gene expression by reactive oxygen. Annu Rev Pharmacol Toxicol 39: 67-101, 1999. (Pubitemid 29222552)
14. Kariya S, Sawada K, Kobayashi T, Karashima T, Shuin T, Nishioka A and Ogawa Y: Combination treatment of hydrogen peroxide and X-rays induces apoptosis in human prostate cancer PC-3 cells. Int J Radiat Oncol Biol Phys 75: 449-454, 2009.
15. Medina VA, Massari NA, Cricco GP, Martín GA, Bergoc RM and Rivera ES: Involvement of hydrogen peroxide in histamine-induced modulation of WM35 human malignant melanoma cell proliferation. Free Radic Biol Med 46: 1510-1515, 2009.
16. Morgado S, Granados MP, Bejarano I, Lopez JJ, Salido GM, Gonzalez A and Pariente JA: Role of intracellular calcium on hydrogen peroxide-induced apoptosis in rat pancreatic acinar AR42J cells. J Appl Biomed 6: 211-224, 2008.
17. Fang Y, DeMarco VG and Nicholl MB: Resveratrol enhances radiation sensitivity in prostate cancer by inhibiting cell proliferation and promoting cell senescence and apoptosis. Cancer Sci 103: 1090-1098, 2012.
18. Fang Y, Herrick EJ and Nicholl MB: A possible role for perforin and granzyme B in resveratrol enhanced radiosensitivity of prostate cancer. J Androl 33: 752-760, 2012.
19. Fang Y, Wei Y, DeMarco V, Chen K, Sharp GC and Braley-Mullen H: Murine FLIP transgene expressed on thyroid epithelial cells promotes resolution of granulomatous experimental autoimmune thyroiditis. Am J Pathol 171: 875-887. 2007. (Pubitemid 47339357)
20. Fang Y, Sharp GC, Yagita H and Braley-Mullen H: A critical role for TRAIL in resolution of granulomatous experimental autoimmune thyroiditis. J Pathol 216: 505-513, 2008.
21. -/- mice by down-regulation of p21 and p27 via AKT pathway. Am J Pathol 180: 650-660, 2012.
22. Johnson DG and Walker CL: Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol 39: 295-312, 1999. (Pubitemid 29222561)
23. Sherr CJ: G1 phaseprogression: Cycling on cue. Cell 79: 551- 555, 1994.
24. 1-to-S phase transition. Mol Cell Biol 15: 2612-2624, 1995.
25. Sherr CJ: D-Type cyclins. Trends Biochem Sci 20: 187-190, 1995.
26. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456-1462, 1995.
27. Zhang H, Xu Q, Krajewski S, Krajewska M, Xie Z, Fuess S, Kitada S, Pawlowski K, Godzik A, and Reed JC: BAR: An apoptosis regulator at the intersection of caspases and BCL2 family proteins. Proc Natl Acad Sci USA 97: 2597-2602, 2000. (Pubitemid 30159216)
28. Griffith TS, Brunner T, Fletcher SM, Green DR and Ferguson TA: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270: 1189-1192, 1995.
29. Fang Y and Braley-Mullen H: Cultured murine thyroid epithelial cells expressing transgenic Fas-associated death domain-like interleukin-1β converting enzyme inhibitory protein are protected from Fas-mediated apoptosis. Endocrinology 149: 1121-1129, 2008.
30. Picardo M, Grammatico P, Roccella F, Roccella M, Grandinetti M, Del Porto G and Passi S: Imbalance in the antioxidant pool in melanoma cells and normal melanocytes from patients with melanoma. J Invest Dermatol 107: 322-326, 1996. (Pubitemid 26284337)
31. Baldi A, Lombardi D, Russo P, Palescandolo E, De Luca A, Santini D, Baldi F, Rossiello L, Dell'Anna ML, Mastrofrancesco A, Maresca V, Flori E, Natali PG, Picardo M and Paggi MG: Ferritin contributes to melanoma progression by modulating cell growth and sensitivity to oxidative stress. Clin Cancer Res 11: 3175-3183, 2005. (Pubitemid 40627862)
32. Bravard A, Cherbonnel-Lasserre C, Reillaudou M, Beaumatin J, Dutrillaux B and Luccioni C: Modifications of the antioxidant enzymes in relation to chromosome imbalances in human melanoma cell lines. Melanoma Res 8: 329-335,1998. (Pubitemid 28442564)
33. Yu J and Kim AK: Effect of taurine on antioxidant enzyme system in B16F10 melanoma cells. Adv Exp Med Biol 643: 491-499, 2009.
34. Kolarova H, Nevrelova P, Bajgar R, Jirova D, Kejlova K and Strnad M: In vitro photodynamic therapy on melanoma cell lines with phthalocyanine. Toxicol In Vitro 21: 249-253, 2007. (Pubitemid 46205090)
35. Posen Y, Kalchenko V, Seger R, Brandis A, Scherz A and Salomon Y: Manipulation of redox signaling in mammalian cells enabled by controlled photogeneration of reactive oxygen species. J Cell Sci 118: 1957-1969, 2005. (Pubitemid 40723839)
36. Ogawa Y Ue H, Tsuzuki K, Tadokoro M, Miyatake K, Sasaki T, Yokota N, Hamada N, Kariya S, Hitomi J, Nishioka A, Nakajima K, Ikeda M, Sano S and Inomata T: New radiosensitization treatment (KORTUC I) using hydrogen peroxide solution-soaked gauze bolus for unresectable and superficially exposed neoplasms. Oncol Rep 19: 1389-1394, 2008.
37. Ogawa Y, Kubota K, Ue H, Tadokoro M, Matsui R, Yamanishi T, Hamada N, Kariya S, Nishioka A, Nakajima H, Tarutani M and Sano S: Safety and effectiveness of a new enzyme-targeting radiosensitization treatment (KORTUC II) for intratumoral injection for low-LET radioresistant tumors. Int J Oncol 39: 553-560, 2011.
38. Gomez Sarosi LA, Rieber MS and Rieber M: Hydrogen peroxide increases a 55-kDa tyrosinase concomitantly with induction of p53-dependent p21/waf1 expression and a greater Bax/Bcl-2 ratio in pigmented melanoma. Biochem Biophys Res Commun 312: 355-359, 2003. (Pubitemid 37445180)
39. Sah NK, Khan Z, Khan GJ and Bisen PS: Structural, functional and therapeutic biology of survivin. Cancer Lett 244: 164-171, 2006. (Pubitemid 44485888)
40. Yamamoto H, Ngan CY and Monden M: Cancer cells survive with survivin. Cancer Sci 99: 1709-1714, 2008.
41. Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8: 61-70, 2008.